stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) EPS (diluted)
RadNet, Inc.'s EPS (diluted) for fiscal 2025 was −$0.25, compared with $0.04 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$0.27. Over the past ten years it has ranged from −$0.29 (fiscal 2020) to $0.66 (fiscal 2018); the current reading is higher than 18% of that period. EPS (diluted) has fallen for 4 consecutive fiscal years. RadNet, Inc. ranks 24th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.25 | — |
| FY2024 | $0.04 | (20.00%) |
| FY2023 | $0.05 | (70.59%) |
| FY2022 | $0.17 | (63.04%) |
| FY2021 | $0.46 | — |
| FY2020 | −$0.29 | — |
| FY2019 | $0.29 | (56.06%) |
| FY2018 | $0.66 | — |
| FY2017 | $0.00 | — |
| FY2016 | $0.15 | (11.76%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.10 | — |
| Mar 2026 | −$0.43 | — |
| Dec 2025 | −$0.01 | — |
| Sep 2025 | $0.07 | (63.16%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ICLR ICON PLC compare | $5.81 |
| CDNA CareDx, Inc. compare | $2.39 |
| QGEN QIAGEN N.V. compare | $1.95 |
| VCYT Veracyte, Inc. compare | $1.55 |
| BLLN BillionToOne, Inc. compare | $0.92 |
| SHC Sotera Health Company compare | $0.60 |
| RDNT RadNet, Inc. | −$0.27 |
| ADPT Adaptive Biotechnologies Corporation compare | −$0.45 |
| GRAL GRAIL, Inc. compare | −$9.50 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RDNT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement